Schedule of Investments (unaudited) March 31, 2021 | BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Common Stocks |
| |||||||
Biotechnology — 18.9% | ||||||||
Acceleron Pharma, Inc.(a)(b) | 38,325 | $ | 5,197,253 | |||||
Acerta Pharma BV, Series B, (Acquired 05/06/15, Cost: $986,402)(c)(d) | 17,146,440 | 2,375,125 | ||||||
Agios Pharmaceuticals, Inc.(a)(b) | 21,625 | 1,116,715 | ||||||
Allakos, Inc.(a)(b) | 22,275 | 2,556,724 | ||||||
Allogene Therapeutics, Inc.(a)(b) | 30,786 | 1,086,746 | ||||||
Alnylam Pharmaceuticals, Inc.(a)(b) | 34,003 | 4,800,884 | ||||||
Amgen, Inc.(a) | 62,397 | 15,524,998 | ||||||
Annexon, Inc., (Acquired 06/26/20, Cost: $190,006)(d) | 15,164 | 422,166 | ||||||
Apellis Pharmaceuticals, Inc.(a)(b) | 15,300 | 656,523 | ||||||
Arcutis Biotherapeutics, Inc.02/03/21(a)(b) | 42,854 | 1,239,766 | ||||||
Arena Pharmaceuticals, Inc.(a)(b) | 14,984 | 1,039,740 | ||||||
Argenx SE, ADR(a)(b) | 4,800 | 1,321,872 | ||||||
Atreca, Inc., Class A(b) | 7,258 | 111,265 | ||||||
Biogen, Inc.(a)(b) | 10,940 | 3,060,465 | ||||||
Biohaven Pharmaceutical Holding Co. Ltd.(a)(b) | 6,445 | 440,516 | ||||||
BioMarin Pharmaceutical, Inc.(a)(b) | 14,814 | 1,118,605 | ||||||
Blueprint Medicines Corp.(a)(b) | 9,623 | 935,644 | ||||||
Bridgebio Pharma, Inc.(a)(b) | 13,427 | 827,103 | ||||||
Cerevel Therapeutics Holdings, Inc.(b) | 12,589 | 172,847 | ||||||
ChemoCentryx, Inc.(a)(b) | 9,383 | 480,785 | ||||||
Connect Biopharma Holdings Ltd.(b) | 12,117 | 224,164 | ||||||
Cytokinetics, Inc.(a)(b) | 16,280 | 378,673 | ||||||
Decibel Therapeutics, Inc.(b) | 25,174 | 285,977 | ||||||
Decibel Therapeutics, Inc., (Acquired 11/02/20, Cost: $198,658)(d) | 21,710 | 237,514 | ||||||
Design Therapeutics, Inc.(b) | 13,967 | 417,613 | ||||||
Dicerna Pharmaceuticals, Inc.(a)(b) | 14,790 | 378,180 | ||||||
Enanta Pharmaceuticals, Inc.(a)(b) | 5,480 | 270,274 | ||||||
Everest Medicines LTD, (Acquired 09/30/20, Cost: $218,631)(d) | 30,500 | 287,836 | ||||||
Exact Sciences Corp.(a)(b) | 14,000 | 1,844,920 | ||||||
Forma Therapeutics Holdings, Inc.(b) | 11,947 | 334,755 | ||||||
Genmab A/S(b) | 14,763 | 4,855,458 | ||||||
Genmab A/S, ADR(a)(b) | 51,161 | 1,679,616 | ||||||
Gilead Sciences, Inc.(a) | 206,984 | 13,377,376 | ||||||
Global Blood Therapeutics, Inc.(a)(b) | �� | 17,269 | 703,712 | |||||
Halozyme Therapeutics, Inc.(a)(b) | 21,055 | 877,783 | ||||||
Immunocore Holdings PLC, ADR(b) | 9,668 | 411,567 | ||||||
Incyte Corp.(a)(b) | 23,637 | 1,920,979 | ||||||
Intellia Therapeutics, Inc.(a)(b) | 6,359 | 510,341 | ||||||
Iovance Biotherapeutics, Inc.(a)(b) | 30,790 | 974,811 | ||||||
Kodiak Sciences, Inc.(a)(b) | 9,010 | 1,021,644 | ||||||
Kronos Bio, Inc., (Acquired 10/09/20, Cost: $260,000), 8/20/2020(d) | 16,099 | 470,301 | ||||||
Krystal Biotech, Inc.(b) | 3,730 | 287,359 | ||||||
Mersana Therapeutics, Inc.(a)(b) | 57,220 | 925,820 | ||||||
Mirati Therapeutics, Inc.(a)(b) | 14,516 | 2,486,591 | ||||||
Molecular Templates, Inc.(a)(b) | 21,176 | 267,241 | ||||||
Neurocrine Biosciences, Inc.(a)(b) | 18,372 | 1,786,677 | ||||||
Prothena Corp. PLC(a)(b) | 21,064 | 529,128 | ||||||
PTC Therapeutics, Inc.(b) | 4,745 | 224,676 | ||||||
Rapt Therapeutics, Inc.(a)(b) | 8,660 | 192,252 | ||||||
Regeneron Pharmaceuticals, Inc.(a)(b) | 11,420 | 5,403,259 | ||||||
Relay Therapeutics, Inc.(b) | 10,918 | 377,435 | ||||||
Remegen Co. Ltd., (Acquired 11/03/20, Cost: $369,944), 11/3/2021(d) | 54,500 | 669,180 | ||||||
Sage Therapeutics, Inc.(a)(b) | 7,085 | 530,312 | ||||||
Sarepta Therapeutics, Inc.(a)(b) | 8,718 | 649,752 |
Security | Shares | Value | ||||||
Biotechnology (continued) | ||||||||
Seagen, Inc.(a)(b) | 65,708 | $ | 9,124,213 | |||||
Seres Therapeutics, Inc.(a)(b) | 11,900 | 245,021 | ||||||
Sigilon Therapeutics, Inc., (Acquired 02/14/20, Cost: $264,000)(d) | 19,555 | 429,406 | ||||||
Stoke Therapeutics, Inc.(a)(b) | 4,431 | 172,100 | ||||||
Taysha Gene Therapies, Inc.(b) | 13,722 | 278,557 | ||||||
Taysha Gene Therapies, Inc. | 17,214 | 349,444 | ||||||
TCR2 Therapeutics, Inc.(a)(b) | 10,160 | 224,333 | ||||||
Vertex Pharmaceuticals, Inc.(a)(b) | 21,723 | 4,668,055 | ||||||
|
| |||||||
105,770,047 | ||||||||
Diversified Financial Services(b) — 0.4% | ||||||||
ARYA Sciences Acquisition Corp. III, Class A | 16,560 | 228,197 | ||||||
BCTG Acquisition Corp. | 8,720 | 96,966 | ||||||
Deerfield Healthcare Technology Acquisitions Corp., Class A(e) | 21,007 | 254,605 | ||||||
Health Assurance Acquisition Corp., Class A | 90,235 | 922,202 | ||||||
Health Sciences Acquisitions Corp. | 13,696 | 153,806 | ||||||
Helix Acquisition Corp., Class A | 11,715 | 119,610 | ||||||
MedTech Acquisition Corp., Class A | 42,753 | 412,566 | ||||||
Therapeutics Acquisition Corp., Class A | 27,000 | 283,770 | ||||||
|
| |||||||
2,471,722 | ||||||||
Health Care Equipment & Supplies — 30.1% | ||||||||
Abbott Laboratories(a) | 241,542 | 28,946,393 | ||||||
ABIOMED, Inc.(a)(b) | 10,709 | 3,413,280 | ||||||
Alcon, Inc.(a)(b) | 103,355 | 7,253,454 | ||||||
Baxter International, Inc.(a) | 71,417 | 6,023,310 | ||||||
Becton Dickinson and Co.(a) | 31,871 | 7,749,434 | ||||||
Boston Scientific Corp.(a)(b) | 372,187 | 14,385,028 | ||||||
Butterfly Network, Inc.(b) | 35,345 | 594,856 | ||||||
DENTSPLY SIRONA, Inc.(a) | 58,050 | 3,704,171 | ||||||
DexCom, Inc.(a)(b) | 9,385 | 3,372,875 | ||||||
Edwards Lifesciences Corp.(a)(b) | 143,505 | 12,002,758 | ||||||
Envista Holdings Corp.(a)(b) | 36,720 | 1,498,176 | ||||||
Intuitive Surgical, Inc.(a)(b) | 16,663 | 12,312,957 | ||||||
Kangji Medical Holdings Ltd.(b) | 264,936 | 317,564 | ||||||
Masimo Corp.(a)(b) | 22,110 | 5,077,783 | ||||||
Medtronic PLC(a) | 152,096 | 17,967,100 | ||||||
Nevro Corp.(a)(b) | 13,928 | 1,942,956 | ||||||
Novocure Ltd.(a)(b) | 5,958 | 787,528 | ||||||
ResMed, Inc.(a) | 29,932 | 5,807,407 | ||||||
Silk Road Medical, Inc.(a)(b) | 9,077 | 459,750 | ||||||
Straumann Holding AG, Registered Shares | 2,745 | 3,427,181 | ||||||
Stryker Corp.(a) | 55,111 | 13,423,937 | ||||||
Teleflex, Inc.(a) | 19,140 | 7,951,904 | ||||||
Zimmer Biomet Holdings, Inc.(a) | 60,537 | 9,690,763 | ||||||
|
| |||||||
168,110,565 | ||||||||
Health Care Providers & Services — 20.5% | ||||||||
Alignment Healthcare, Inc.(b)(e) | 50,071 | 1,098,057 | ||||||
Amedisys, Inc.(a)(b) | 19,757 | 5,231,456 | ||||||
AmerisourceBergen Corp.(a) | 14,280 | 1,686,040 | ||||||
Anthem, Inc.(a) | 35,497 | 12,741,648 | ||||||
Cardinal Health, Inc.(a) | 64,565 | 3,922,324 | ||||||
Centene Corp.(a)(b) | 99,507 | 6,359,492 | ||||||
Cigna Corp.(a) | 63,694 | 15,397,388 | ||||||
Encompass Health Corp.(a) | 40,167 | 3,289,677 | ||||||
Guardant Health, Inc.(a)(b) | 7,365 | 1,124,267 | ||||||
Henry Schein, Inc.(a)(b) | 34,520 | 2,390,165 | ||||||
Humana, Inc.(a) | 35,650 | 14,946,263 | ||||||
Innovage Holding Corp.(b) | 13,434 | 346,463 | ||||||
LHC Group, Inc.(a)(b) | 20,224 | 3,867,031 |
SCHEDULE OF INVESTMENTS | 1 |
Schedule of Investments (unaudited) (continued) March 31, 2021 | BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Health Care Providers & Services (continued) | ||||||||
McKesson Corp.(a) | 6,180 | $ | 1,205,347 | |||||
Oak Street Health, Inc.(a)(b) | 54,700 | 2,968,569 | ||||||
Quest Diagnostics, Inc.(a) | 12,824 | 1,645,832 | ||||||
UnitedHealth Group, Inc.(a)(f) | 97,849 | 36,406,677 | ||||||
|
| |||||||
114,626,696 | ||||||||
Health Care Technology — 0.7% | ||||||||
Teladoc Health, Inc.(a)(b) | 21,980 | 3,994,865 | ||||||
|
| |||||||
Insurance — 0.1% | ||||||||
GoHealth, Inc., Class A(b) | 36,551 | 427,281 | ||||||
|
| |||||||
Internet & Direct Marketing Retail — 0.4% | ||||||||
JD Health International, Inc., (Acquired 12/01/20, | 163,250 | 2,296,536 | ||||||
|
| |||||||
Life Sciences Tools & Services — 8.2% | ||||||||
Agilent Technologies, Inc.(a) | 13,960 | 1,774,874 | ||||||
Avantor, Inc.(a)(b) | 115,584 | 3,343,845 | ||||||
Illumina, Inc.(a)(b) | 14,027 | 5,387,210 | ||||||
IQVIA Holdings, Inc.(a)(b) | 37,863 | 7,312,860 | ||||||
PPD, Inc.(a)(b) | 95,400 | 3,609,936 | ||||||
Thermo Fisher Scientific, Inc.(a) | 36,003 | 16,431,049 | ||||||
WuXi AppTec Co. Ltd., Class H(g) | 210,485 | 4,156,508 | ||||||
Wuxi Biologics Cayman, Inc.(b)(g) | 297,500 | 3,751,697 | ||||||
|
| |||||||
45,767,979 | ||||||||
Pharmaceuticals — 18.7% | ||||||||
Bristol-Myers Squibb Co.(a) | 167,023 | 10,544,162 | ||||||
Daiichi Sankyo Co. Ltd | 37,100 | 1,082,421 | ||||||
Eisai Co. Ltd. | 24,300 | 1,633,301 | ||||||
Elanco Animal Health, Inc.(b) | 65,535 | 1,930,006 | ||||||
Eli Lilly & Co.(a) | 91,878 | 17,164,648 | ||||||
Hansoh Pharmaceutical Group Co. Ltd.(b)(g) | 882,438 | 4,233,055 | ||||||
Horizon Therapeutics PLC(a)(b) | 19,295 | 1,775,912 | ||||||
Hua Medicine(b)(e)(g) | 735,105 | 420,784 | ||||||
Johnson & Johnson(a) | 151,324 | 24,870,099 | ||||||
Merck & Co., Inc.(a) | 73,837 | 5,692,094 | ||||||
Merck KGaA | 17,316 | 2,961,972 | ||||||
Nektar Therapeutics(a)(b) | 24,513 | 490,260 | ||||||
Pfizer, Inc.(a) | 309,548 | 11,214,924 | ||||||
Roche Holding AG | 7,972 | 2,582,474 | ||||||
Sanofi | 68,800 | 6,803,230 | ||||||
Sanofi, ADR(a) | 54,625 | 2,701,752 | ||||||
Zoetis, Inc.(a) | 54,489 | 8,580,928 | ||||||
|
| |||||||
104,682,022 | ||||||||
|
| |||||||
Total Common Stocks — 98.0% | 548,147,713 | |||||||
|
|
Security | Benefical Interest (000) | Value | ||||||
Other Interests | ||||||||
Pharmaceuticals — 0.1% | ||||||||
Afferent Pharmaceuticals, Inc.(c) | $ | 190 | $ | 270,027 | ||||
|
| |||||||
Total Other Interests — 0.1% | 270,027 | |||||||
|
| |||||||
Shares | ||||||||
Preferred Securities | ||||||||
Preferred Stocks — 0.7%(d) | ||||||||
Biotechnology — 0.4% | ||||||||
Cellarity, Inc., Series B, (Acquired 01/15/21, | 44,167 | 265,002 | ||||||
Acumen Pharmaceuticals, Inc., Series B, (Acquired 11/20/20, Cost: $348,001)(c) | 136,471 | 348,001 | ||||||
Affinvax, Inc., (Acquired 01/06/21, Cost: $199,992)(c) | 6,331 | 199,992 | ||||||
Ambrx Biopharma, Inc.(c) | ||||||||
Series A, (Acquired 11/06/20, Cost: $250,001) | 159,931 | 289,475 | ||||||
Series B, (Acquired 11/06/20, Cost: $250,001) | 143,938 | 260,528 | ||||||
Connect Biopharma Holdings Ltd., Series C, (Acquired 12/01/20, Cost: $250,023) | 22,809 | 402,275 | ||||||
Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $149,465)(c) | 126,665 | 163,398 | ||||||
Imago Biosciences, Inc., (Acquired 11/12/20, Cost: $235,002)(c) | 194,570 | 258,778 | ||||||
Neurogene, Inc., Series B, (Acquired 12/14/20, Cost: $156,340)(c) | 64,074 | 156,341 | ||||||
|
| |||||||
2,343,790 | ||||||||
Health Care Equipment & Supplies — 0.2% | ||||||||
Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $1,070,001)(c) | 367,395 | 1,070,001 | ||||||
|
| |||||||
Pharmaceuticals — 0.1% | ||||||||
Insitro, Inc., Series C, (Acquired 03/10/21, Cost: $560,001)(c) | 30,616 | 560,000 | ||||||
|
| |||||||
Total Preferred Stocks — 0.7% | 3,973,791 | |||||||
|
| |||||||
Total Preferred Securities — 0.7% | 3,973,791 | |||||||
|
| |||||||
Warrants | ||||||||
Biotechnology — 0.0% | ||||||||
Cerevel Therapeutics Holdings, Inc. | 4,196 | 17,707 | ||||||
|
| |||||||
Diversified Financial Services(b) — 0.0% | ||||||||
Deerfield Healthcare Technology Acquisitions Corp. (Expires 07/16/2025) | 4,201 | 12,183 | ||||||
Health Assurance Acquisition Corp. (Expires 11/12/2025) | 22,558 | 58,425 | ||||||
MedTech Acquisition Corp. (Expires 12/18/2025) | 14,251 | 15,676 | ||||||
|
| |||||||
86,284 |
2 |
Schedule of Investments (unaudited) (continued) March 31, 2021 | BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Health Care Equipment & Supplies — 0.0% |
| |||||||
Butterfly Network, Inc. (Expires 05/27/2025)(b) | 11,781 | $ | 75,988 | |||||
|
| |||||||
Pharmaceuticals — 0.0% | ||||||||
Nuvation Bio, Inc. (Expires 07/07/2025)(b) | 4,050 | 10,814 | ||||||
|
| |||||||
Total Warrants — 0.0% | 190,793 | |||||||
|
| |||||||
Total Long-Term Investments — 98.8% | 552,582,324 | |||||||
|
| |||||||
Short-Term Securities | ||||||||
Money Market Funds — 2.2% | ||||||||
BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.01%(h)(i) | 11,483,604 | 11,483,604 | ||||||
SL Liquidity Series, LLC, Money Market Series, 0.16%(h)(i)(j) | 525,809 | 525,967 | ||||||
|
| |||||||
Total Short-Term Securities — 2.2% |
| 12,009,571 | ||||||
|
| |||||||
Total Investments Before Options Written — 101.0% |
| 564,591,895 | ||||||
|
| |||||||
Options Written — (1.1)% |
| (5,981,283 | ) | |||||
|
| |||||||
Total Investments, Net of Options Written — 99.9% |
| 558,610,612 | ||||||
Other Assets Less Liabilities — 0.1% | 476,322 | |||||||
|
| |||||||
Net Assets — 100.0% | $ | 559,086,934 | ||||||
|
|
(a) | All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
(b) | Non-income producing security. |
(c) | Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy. |
(d) | Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $11,161,855, representing 2.00% of its net assets as of period end, and an original cost of $7,722,827. |
(e) | All or a portion of this security is on loan. |
(f) | All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
(g) | Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors. |
(h) | Affiliate of the Trust. |
(i) | Annualized 7-day yield as of period end. |
(j) | All or a portion of this security was purchased with the cash collateral from loaned securities. |
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the period ended March 31, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
Affiliated Issuer | Value at 12/31/20 | Purchases at Cost | Proceeds from Sales | Net Realized Gain (Loss) | Change in Unrealized Appreciation (Depreciation) | Value at 03/31/21 | Shares Held at 03/31/21 | Income | Capital Gain Distributions from Underlying Funds | |||||||||||||||||||||||||||
BlackRock Liquidity Funds, T-Fund, Institutional Class | $ | 13,774,637 | $ | — | $ | (2,291,033 | )(a) | $ | — | $ | — | $ | 11,483,604 | 11,483,604 | $ | 526 | $ | — | ||||||||||||||||||
SL Liquidity Series, LLC, Money Market Series | 102,701 | 423,275 | (a) | — | — | (9 | ) | 525,967 | 525,809 | 760(b | ) | — | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||||||
$ | — | $ | (9 | ) | $ | 12,009,571 | $ | 1,286 | $ | — | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
(a) | Represents net amount purchased (sold). |
(b) | All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||
Call | ||||||||||||||||||||||||
Baxter International, Inc. | 59 | 04/01/21 | USD | 80.50 | USD | 498 | $ | (24,190 | ) | |||||||||||||||
Boston Scientific Corp. | 351 | 04/01/21 | USD | 39.00 | USD | 1,357 | (2,457 | ) | ||||||||||||||||
Edwards Lifesciences Corp. | 112 | 04/01/21 | USD | 90.00 | USD | 937 | (10,640 | ) |
SCHEDULE OF INVESTMENTS | 3 |
Schedule of Investments (unaudited) (continued) March 31, 2021 | BlackRock Health Sciences Trust (BME) |
Exchange-Traded Options Written (continued)
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||
Call (continued) | ||||||||||||||||||||||||
Gilead Sciences, Inc. | 398 | 04/01/21 | USD | 66.50 | USD | 2,572 | $ | (995 | ) | |||||||||||||||
Intuitive Surgical, Inc. | 12 | 04/01/21 | USD | 797.50 | USD | 887 | (5,160 | ) | ||||||||||||||||
McKesson Corp. | 6 | 04/01/21 | USD | 187.50 | USD | 117 | (4,800 | ) | ||||||||||||||||
Abbott Laboratories | 174 | 04/09/21 | USD | 125.74 | USD | 2,085 | (3,193 | ) | ||||||||||||||||
AmerisourceBergen Corp. | 27 | 04/09/21 | USD | 107.00 | USD | 319 | (30,105 | ) | ||||||||||||||||
Amgen, Inc. | 50 | 04/09/21 | USD | 230.00 | USD | 1,244 | (95,250 | ) | ||||||||||||||||
Anthem, Inc. | 51 | 04/09/21 | USD | 335.00 | USD | 1,831 | (126,990 | ) | ||||||||||||||||
Becton Dickinson and Co. | 24 | 04/09/21 | USD | 255.00 | USD | 584 | (600 | ) | ||||||||||||||||
Biogen, Inc. | 25 | 04/09/21 | USD | 282.50 | USD | 699 | (13,875 | ) | ||||||||||||||||
Bristol-Myers Squibb Co. | 84 | 04/09/21 | USD | 63.00 | USD | 530 | (6,636 | ) | ||||||||||||||||
Cigna Corp. | 33 | 04/09/21 | USD | 237.50 | USD | 798 | (21,697 | ) | ||||||||||||||||
Humana, Inc. | 37 | 04/09/21 | USD | 410.00 | USD | 1,551 | (45,325 | ) | ||||||||||||||||
Illumina, Inc. | 22 | 04/09/21 | USD | 455.00 | USD | 845 | (6,160 | ) | ||||||||||||||||
Johnson & Johnson | 273 | 04/09/21 | USD | 162.50 | USD | 4,487 | (77,805 | ) | ||||||||||||||||
McKesson Corp. | 6 | 04/09/21 | USD | 190.00 | USD | 117 | (4,185 | ) | ||||||||||||||||
Medtronic PLC | 142 | 04/09/21 | USD | 121.00 | USD | 1,677 | (7,455 | ) | ||||||||||||||||
Nektar Therapeutics | 98 | 04/09/21 | USD | 24.50 | USD | 196 | (7,840 | ) | ||||||||||||||||
Vertex Pharmaceuticals, Inc. | 70 | 04/09/21 | USD | 222.50 | USD | 1,504 | (13,825 | ) | ||||||||||||||||
ABIOMED, Inc. | 21 | 04/16/21 | USD | 340.00 | USD | 669 | (5,355 | ) | ||||||||||||||||
Acceleron Pharma, Inc. | 96 | 04/16/21 | USD | 140.00 | USD | 1,302 | (37,440 | ) | ||||||||||||||||
Agilent Technologies, Inc. | 55 | 04/16/21 | USD | 135.00 | USD | 699 | (1,650 | ) | ||||||||||||||||
Agios Pharmaceuticals, Inc. | 36 | 04/16/21 | USD | 55.00 | USD | 186 | (3,780 | ) | ||||||||||||||||
Alcon, Inc. | 117 | 04/16/21 | USD | 75.00 | USD | 821 | (11,115 | ) | ||||||||||||||||
Allakos, Inc. | 42 | 04/16/21 | USD | 130.00 | USD | 482 | (11,655 | ) | ||||||||||||||||
Allogene Therapeutics, Inc. | 123 | 04/16/21 | USD | 35.00 | USD | 434 | (29,520 | ) | ||||||||||||||||
Alnylam Pharmaceuticals, Inc. | 72 | 04/16/21 | USD | 170.00 | USD | 1,017 | (9,720 | ) | ||||||||||||||||
Amedisys, Inc. | 72 | 04/16/21 | USD | 280.00 | USD | 1,906 | (38,520 | ) | ||||||||||||||||
Amgen, Inc | 71 | 04/16/21 | USD | 240.00 | USD | 1,767 | (76,325 | ) | ||||||||||||||||
Anthem, Inc. | 51 | 04/16/21 | USD | 330.00 | USD | 1,831 | (155,040 | ) | ||||||||||||||||
Apellis Pharmaceuticals, Inc. | 17 | 04/16/21 | USD | 50.00 | USD | 73 | (595 | ) | ||||||||||||||||
Arcutis Biotherapeutics, Inc. | 21 | 04/16/21 | USD | 40.00 | USD | 61 | (1,313 | ) | ||||||||||||||||
Arena Pharmaceuticals, Inc. | 59 | 04/16/21 | USD | 80.00 | USD | 409 | (1,475 | ) | ||||||||||||||||
Argenx SE | 6 | 04/16/21 | USD | 320.00 | USD | 165 | (2,940 | ) | ||||||||||||||||
Avantor, Inc. | 259 | 04/16/21 | USD | 30.00 | USD | 749 | (9,713 | ) | ||||||||||||||||
Baxter International, Inc. | 145 | 04/16/21 | USD | 82.50 | USD | 1,223 | (41,325 | ) | ||||||||||||||||
Becton Dickinson and Co. | 49 | 04/16/21 | USD | 260.00 | USD | 1,191 | (1,715 | ) | ||||||||||||||||
Biohaven Pharmaceutical Holding Co. Ltd. | 25 | 04/16/21 | USD | 90.00 | USD | 171 | (2,250 | ) | ||||||||||||||||
BioMarin Pharmaceutical, Inc. | 34 | 04/16/21 | USD | 95.00 | USD | 257 | (255 | ) | ||||||||||||||||
BioMarin Pharmaceutical, Inc. | 101 | 04/16/21 | USD | 85.00 | USD | 763 | (1,515 | ) | ||||||||||||||||
Blueprint Medicines Corp. | 19 | 04/16/21 | USD | 110.00 | USD | 185 | (7,030 | ) | ||||||||||||||||
Bridgebio Pharma, Inc. | 39 | 04/16/21 | USD | 75.00 | USD | 240 | (8,190 | ) | ||||||||||||||||
Bristol-Myers Squibb Co. | 170 | 04/16/21 | USD | 62.50 | USD | 1,073 | (24,650 | ) | ||||||||||||||||
Centene Corp. | 72 | 04/16/21 | USD | 62.50 | USD | 460 | (17,820 | ) | ||||||||||||||||
ChemoCentryx, Inc. | 20 | 04/16/21 | USD | 75.00 | USD | 102 | (10,000 | ) | ||||||||||||||||
Cigna Corp. | 80 | 04/16/21 | USD | 220.00 | USD | 1,934 | (179,600 | ) | ||||||||||||||||
Cytokinetics, Inc. | 32 | 04/16/21 | USD | 24.00 | USD | 74 | (4,480 | ) | ||||||||||||||||
DENTSPLY SIRONA, Inc. | 135 | 04/16/21 | USD | 57.50 | USD | 861 | (85,050 | ) | ||||||||||||||||
Dicerna Pharmaceuticals, Inc. | 29 | 04/16/21 | USD | 30.00 | USD | 74 | (870 | ) | ||||||||||||||||
Edwards Lifesciences Corp. | 148 | 04/16/21 | USD | 85.00 | USD | 1,238 | (17,020 | ) | ||||||||||||||||
Encompass Health Corp. | 80 | 04/16/21 | USD | 85.00 | USD | 655 | (5,800 | ) | ||||||||||||||||
Envista Holdings Corp. | 130 | 04/16/21 | USD | 41.00 | USD | 530 | (22,945 | ) | ||||||||||||||||
Exact Sciences Corp. | 28 | 04/16/21 | USD | 150.00 | USD | 369 | (1,820 | ) | ||||||||||||||||
Genmab A/S, ADR | 88 | 04/16/21 | USD | 45.23 | USD | 289 | (41 | ) | ||||||||||||||||
Global Blood Therapeutics, Inc. | 13 | 04/16/21 | USD | 60.00 | USD | 53 | (325 | ) | ||||||||||||||||
Guardant Health, Inc. | 27 | 04/16/21 | USD | 155.00 | USD | 412 | (14,040 | ) | ||||||||||||||||
Halozyme Therapeutics, Inc. | 103 | 04/16/21 | USD | 50.00 | USD | 429 | (9,270 | ) | ||||||||||||||||
Henry Schein, Inc. | 61 | 04/16/21 | USD | 65.00 | USD | 422 | (27,450 | ) | ||||||||||||||||
Henry Schein, Inc. | 61 | 04/16/21 | USD | 67.50 | USD | 422 | (15,707 | ) | ||||||||||||||||
Humana, Inc. | 43 | 04/16/21 | USD | 410.00 | USD | 1,803 | (62,350 | ) | ||||||||||||||||
Incyte Corp. | 118 | 04/16/21 | USD | 82.50 | USD | 959 | (20,945 | ) | ||||||||||||||||
Intellia Therapeutics, Inc. | 8 | 04/16/21 | USD | 75.00 | USD | 64 | (7,200 | ) | ||||||||||||||||
Intuitive Surgical, Inc. | 14 | 04/16/21 | USD | 730.00 | USD | 1,035 | (30,170 | ) |
4 |
|
Schedule of Investments (unaudited) (continued) March 31, 2021 | BlackRock Health Sciences Trust (BME) |
Exchange-Traded Options Written (continued)
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||
Call (continued) | ||||||||||||||||||||||||
Iovance Biotherapeutics, Inc. | 61 | 04/16/21 | USD | 50.00 | USD | 193 | $ | (2,440 | ) | |||||||||||||||
IQVIA Holdings, Inc. | 100 | 04/16/21 | USD | 190.00 | USD | 1,931 | (58,500 | ) | ||||||||||||||||
Kodiak Sciences, Inc. | 13 | 04/16/21 | USD | 155.00 | USD | 147 | (1,885 | ) | ||||||||||||||||
LHC Group, Inc. | 18 | 04/16/21 | USD | 209.00 | USD | 344 | (2,112 | ) | ||||||||||||||||
Masimo Corp. | 19 | 04/16/21 | USD | 275.00 | USD | 436 | (855 | ) | ||||||||||||||||
Masimo Corp. | 91 | 04/16/21 | USD | 240.00 | USD | 2,090 | (21,157 | ) | ||||||||||||||||
Medtronic PLC | 95 | 04/16/21 | USD | 120.00 | USD | 1,122 | (12,160 | ) | ||||||||||||||||
Merck & Co., Inc. | 148 | 04/16/21 | USD | 77.50 | USD | 1,141 | (14,356 | ) | ||||||||||||||||
Mersana Therapeutics, Inc. | 35 | 04/16/21 | USD | 22.50 | USD | 57 | (525 | ) | ||||||||||||||||
Molecular Templates, Inc. | 42 | 04/16/21 | USD | 15.00 | USD | 53 | (1,575 | ) | ||||||||||||||||
Neurocrine Biosciences, Inc. | 46 | 04/16/21 | USD | 115.00 | USD | 447 | (1,035 | ) | ||||||||||||||||
Nevro Corp. | 24 | 04/16/21 | USD | 190.00 | USD | 335 | (3,600 | ) | ||||||||||||||||
PPD, Inc. | 237 | 04/16/21 | USD | 40.00 | USD | 897 | (7,703 | ) | ||||||||||||||||
Prothena PLC | 21 | 04/16/21 | USD | 23.05 | USD | 53 | (6,798 | ) | ||||||||||||||||
Rapt Therapeutics, Inc. | 17 | 04/16/21 | USD | 22.50 | USD | 38 | (3,740 | ) | ||||||||||||||||
ResMed, Inc. | 51 | 04/16/21 | USD | 210.00 | USD | 990 | (1,020 | ) | ||||||||||||||||
Sage Therapeutics, Inc. | 13 | 04/16/21 | USD | 87.50 | USD | 97 | (1,235 | ) | ||||||||||||||||
Sanofi — ADR | 109 | 04/16/21 | USD | 48.45 | USD | 539 | (16,418 | ) | ||||||||||||||||
Sarepta Therapeutics, Inc. | 34 | 04/16/21 | USD | 95.00 | USD | 253 | (2,040 | ) | ||||||||||||||||
Seagen, Inc. | 129 | 04/16/21 | USD | 174.00 | USD | 1,791 | (609 | ) | ||||||||||||||||
Seres Therapeutics, Inc. | 43 | 04/16/21 | USD | 30.00 | USD | 89 | (860 | ) | ||||||||||||||||
Seres Therapeutics, Inc. | 2 | 04/16/21 | USD | 25.00 | USD | 4 | (95 | ) | ||||||||||||||||
Silk Road Medical, Inc. | 6 | 04/16/21 | USD | 60.00 | USD | 30 | (300 | ) | ||||||||||||||||
Stryker Corp. | 100 | 04/16/21 | USD | 248.25 | USD | 2,436 | (23,490 | ) | ||||||||||||||||
TCR2 Therapeutics, Inc. | 20 | 04/16/21 | USD | 35.00 | USD | 44 | (3,000 | ) | ||||||||||||||||
Teladoc Health, Inc. | 39 | 04/16/21 | USD | 300.00 | USD | 709 | (254 | ) | ||||||||||||||||
Teleflex, Inc. | 38 | 04/16/21 | USD | 420.00 | USD | 1,579 | (30,590 | ) | ||||||||||||||||
Thermo Fisher Scientific, Inc. | 75 | 04/16/21 | USD | 500.00 | USD | 3,423 | (7,875 | ) | ||||||||||||||||
UnitedHealth Group, Inc. | 194 | 04/16/21 | USD | 340.00 | USD | 7,218 | (663,480 | ) | ||||||||||||||||
Zimmer Biomet Holdings, Inc. | 74 | 04/16/21 | USD | 165.00 | USD | 1,185 | (14,060 | ) | ||||||||||||||||
Zoetis, Inc. | 81 | 04/16/21 | USD | 160.00 | USD | 1,276 | (15,187 | ) | ||||||||||||||||
Amgen, Inc. | 53 | 04/23/21 | USD | 250.00 | USD | 1,319 | (26,765 | ) | ||||||||||||||||
Centene Corp. | 75 | 04/23/21 | USD | 62.00 | USD | 479 | (22,725 | ) | ||||||||||||||||
Cigna Corp. | 74 | 04/23/21 | USD | 242.50 | USD | 1,789 | (47,175 | ) | ||||||||||||||||
Eli Lilly & Co. | 45 | 04/23/21 | USD | 220.00 | USD | 841 | (4,500 | ) | ||||||||||||||||
Eli Lilly & Co. | 217 | 04/23/21 | USD | 197.50 | USD | 4,054 | (30,380 | ) | ||||||||||||||||
Humana, Inc. | 16 | 04/23/21 | USD | 415.00 | USD | 671 | (20,560 | ) | ||||||||||||||||
Intuitive Surgical, Inc. | 9 | 04/23/21 | USD | 755.00 | USD | 665 | (14,265 | ) | ||||||||||||||||
Johnson & Johnson | 93 | 04/23/21 | USD | 165.00 | USD | 1,528 | (25,389 | ) | ||||||||||||||||
McKesson Corp. | 6 | 04/23/21 | USD | 192.50 | USD | 117 | (4,515 | ) | ||||||||||||||||
Medtronic PLC | 56 | 04/23/21 | USD | 118.00 | USD | 662 | (12,740 | ) | ||||||||||||||||
Regeneron Pharmaceuticals, Inc. | 33 | 04/23/21 | USD | 485.00 | USD | 1,561 | (31,680 | ) | ||||||||||||||||
Regeneron Pharmaceuticals, Inc. | 10 | 04/23/21 | USD | 500.00 | USD | 473 | (5,550 | ) | ||||||||||||||||
Teladoc Health, Inc. | 23 | 04/23/21 | USD | 212.50 | USD | 418 | (3,761 | ) | ||||||||||||||||
UnitedHealth Group, Inc. | 56 | 04/23/21 | USD | 355.00 | USD | 2,084 | (120,260 | ) | ||||||||||||||||
Abbott Laboratories | 140 | 04/30/21 | USD | 122.00 | USD | 1,678 | (35,770 | ) | ||||||||||||||||
AmerisourceBergen Corp. | 27 | 04/30/21 | USD | 122.00 | USD | 319 | (6,008 | ) | ||||||||||||||||
Becton Dickinson and Co. | 48 | 04/30/21 | USD | 252.50 | USD | 1,167 | (13,560 | ) | ||||||||||||||||
Biogen, Inc. | 16 | 04/30/21 | USD | 282.50 | USD | 448 | (20,560 | ) | ||||||||||||||||
Boston Scientific Corp. | 781 | 04/30/21 | USD | 40.00 | USD | 3,019 | (48,422 | ) | ||||||||||||||||
Bristol-Myers Squibb Co. | 203 | 04/30/21 | USD | 62.00 | USD | 1,282 | (47,908 | ) | ||||||||||||||||
Cardinal Health, Inc. | 65 | 04/30/21 | USD | 59.50 | USD | 395 | (18,037 | ) | ||||||||||||||||
Centene Corp. | 103 | 04/30/21 | USD | 64.50 | USD | 658 | (31,363 | ) | ||||||||||||||||
Edwards Lifesciences Corp. | 285 | 04/30/21 | USD | 84.00 | USD | 2,384 | (90,487 | ) | ||||||||||||||||
Eli Lilly & Co. | 87 | 04/30/21 | USD | 187.50 | USD | 1,625 | (53,505 | ) | ||||||||||||||||
Exact Sciences Corp. | 25 | 04/30/21 | USD | 145.00 | USD | 329 | (8,313 | ) | ||||||||||||||||
Illumina, Inc. | 31 | 04/30/21 | USD | 440.00 | USD | 1,191 | (10,850 | ) | ||||||||||||||||
Intuitive Surgical, Inc. | 9 | 04/30/21 | USD | 760.00 | USD | 665 | (13,635 | ) | ||||||||||||||||
Intuitive Surgical, Inc. | 10 | 04/30/21 | USD | 755.00 | USD | 739 | (18,500 | ) | ||||||||||||||||
Mckesson Corp | 5 | 04/30/21 | USD | 197.50 | USD | 98 | (3,063 | ) | ||||||||||||||||
Medtronic PLC | 125 | 04/30/21 | USD | 117.00 | USD | 1,477 | (44,375 | ) | ||||||||||||||||
Pfizer, Inc. | 663 | 04/30/21 | USD | 35.50 | USD | 2,402 | (82,543 | ) |
SCHEDULE OF INVESTMENTS | 5 |
Schedule of Investments (unaudited) (continued) March 31, 2021 | BlackRock Health Sciences Trust (BME) |
Exchange-Traded Options Written (continued)
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||
Call (continued) | ||||||||||||||||||||||||
Teladoc Health, Inc. | 9 | 04/30/21 | USD | 225.00 | USD | 164 | $ | (1,067 | ) | |||||||||||||||
UnitedHealth Group, Inc. | 70 | 04/30/21 | USD | 370.00 | USD | 2,604 | (81,725 | ) | ||||||||||||||||
Alcon AG | 137 | 05/04/21 | USD | 73.97 | USD | 961 | (26,873 | ) | ||||||||||||||||
Abbott Laboratories | 384 | 05/07/21 | USD | 124.11 | USD | 4,602 | (72,315 | ) | ||||||||||||||||
Boston Scientific Corp. | 282 | 05/07/21 | USD | 40.00 | USD | 1,090 | (20,022 | ) | ||||||||||||||||
Bristol-Myers Squibb Co. | 85 | 05/07/21 | USD | 64.00 | USD | 537 | (12,112 | ) | ||||||||||||||||
Cardinal Health, Inc. | 56 | 05/07/21 | USD | 63.00 | USD | 340 | (9,380 | ) | ||||||||||||||||
Centene Corp. | 128 | 05/07/21 | USD | 66.00 | USD | 818 | (40,832 | ) | ||||||||||||||||
Humana, Inc. | 39 | 05/07/21 | USD | 432.50 | USD | 1,635 | (35,100 | ) | ||||||||||||||||
Abbott Laboratories | 219 | 05/21/21 | USD | 125.00 | USD | 2,625 | (41,719 | ) | ||||||||||||||||
ABIOMED, Inc. | 19 | 05/21/21 | USD | 320.00 | USD | 606 | (40,375 | ) | ||||||||||||||||
Acceleron Pharma, Inc. | 49 | 05/21/21 | USD | 145.00 | USD | 664 | (35,280 | ) | ||||||||||||||||
Agios Pharmaceuticals, Inc. | 46 | 05/21/21 | USD | 55.00 | USD | 238 | (17,250 | ) | ||||||||||||||||
Alcon, Inc. | 137 | 05/21/21 | USD | 75.00 | USD | 961 | (16,097 | ) | ||||||||||||||||
Allakos, Inc. | 42 | 05/21/21 | USD | 135.00 | USD | 482 | (18,270 | ) | ||||||||||||||||
Alnylam Pharmaceuticals, Inc. | 57 | 05/21/21 | USD | 150.00 | USD | 805 | (42,465 | ) | ||||||||||||||||
Amedisys, Inc. | 4 | 05/21/21 | USD | 280.00 | USD | 106 | (3,240 | ) | ||||||||||||||||
Amgen, Inc. | 60 | 05/21/21 | USD | 260.00 | USD | 1,493 | (25,800 | ) | ||||||||||||||||
Anthem, Inc. | 52 | 05/21/21 | USD | 360.00 | USD | 1,867 | (80,600 | ) | ||||||||||||||||
Apellis Pharmaceuticals, Inc. | 41 | 05/21/21 | USD | 50.00 | USD | 176 | (11,275 | ) | ||||||||||||||||
Arcutis Biotherapeutics, Inc. | 63 | 05/21/21 | USD | 35.00 | USD | 182 | (12,442 | ) | ||||||||||||||||
Argenx SE | 12 | 05/21/21 | USD | 320.00 | USD | 330 | (6,120 | ) | ||||||||||||||||
Avantor, Inc. | 71 | 05/21/21 | USD | 32.50 | USD | 205 | (3,373 | ) | ||||||||||||||||
Avantor, Inc. | 109 | 05/21/21 | USD | 30.00 | USD | 315 | (12,807 | ) | ||||||||||||||||
Baxter International, Inc. | 67 | 05/21/21 | USD | 82.50 | USD | 565 | (28,810 | ) | ||||||||||||||||
Blueprint Medicines Corp. | 17 | 05/21/21 | USD | 105.00 | USD | 165 | (7,990 | ) | ||||||||||||||||
Bridgebio Pharma, Inc. | 12 | 05/21/21 | USD | 70.00 | USD | 74 | (2,550 | ) | ||||||||||||||||
Bristol-Myers Squibb Co. | 92 | 05/21/21 | USD | 65.00 | USD | 581 | (12,236 | ) | ||||||||||||||||
Cardinal Health, Inc. | 124 | 05/21/21 | USD | 62.50 | USD | 753 | (25,420 | ) | ||||||||||||||||
ChemoCentryx, Inc. | 15 | 05/21/21 | USD | 65.00 | USD | 77 | (3,825 | ) | ||||||||||||||||
Cigna Corp. | 32 | 05/21/21 | USD | 230.00 | USD | 774 | (56,720 | ) | ||||||||||||||||
Cigna Corp. | 80 | 05/21/21 | USD | 240.00 | USD | 1,934 | (93,600 | ) | ||||||||||||||||
Cytokinetics, Inc. | 29 | 05/21/21 | USD | 26.00 | USD | 67 | (6,815 | ) | ||||||||||||||||
DENTSPLY SIRONA, Inc. | 85 | 05/21/21 | USD | 62.50 | USD | 542 | (33,150 | ) | ||||||||||||||||
DexCom, Inc. | 35 | 05/21/21 | USD | 370.00 | USD | 1,258 | (74,200 | ) | ||||||||||||||||
Dicerna Pharmaceuticals, Inc. | 27 | 05/21/21 | USD | 30.00 | USD | 69 | (3,240 | ) | ||||||||||||||||
Enanta Pharmaceuticals, Inc. | 4 | 05/21/21 | USD | 55.00 | USD | 20 | (960 | ) | ||||||||||||||||
Encompass Health Corp. | 72 | 05/21/21 | USD | 85.00 | USD | 590 | (14,940 | ) | ||||||||||||||||
Envista Holdings Corp. | 9 | 05/21/21 | USD | 44.00 | USD | 37 | (1,323 | ) | ||||||||||||||||
Genmab A/S, ADR | 63 | 05/21/21 | USD | 35.00 | USD | 207 | (10,080 | ) | ||||||||||||||||
Global Blood Therapeutics, Inc. | 52 | 05/21/21 | USD | 50.00 | USD | 212 | (4,550 | ) | ||||||||||||||||
Horizon Therapeutics PLC | 37 | 05/21/21 | USD | 105.00 | USD | 341 | (10,545 | ) | ||||||||||||||||
Horizon Therapeutics PLC | 36 | 05/21/21 | USD | 100.00 | USD | 331 | (15,480 | ) | ||||||||||||||||
Intellia Therapeutics, Inc. | 16 | 05/21/21 | USD | 72.00 | USD | 128 | (26,159 | ) | ||||||||||||||||
Intuitive Surgical, Inc. | 9 | 05/21/21 | USD | 750.00 | USD | 665 | (23,445 | ) | ||||||||||||||||
IQVIA Holdings, Inc. | 43 | 05/21/21 | USD | 195.00 | USD | 831 | (31,175 | ) | ||||||||||||||||
Johnson & Johnson | 209 | 05/21/21 | USD | 165.00 | USD | 3,435 | (86,735 | ) | ||||||||||||||||
Kodiak Sciences, Inc. | 21 | 05/21/21 | USD | 150.00 | USD | 238 | (7,193 | ) | ||||||||||||||||
LHC Group, Inc. | 58 | 05/21/21 | USD | 210.00 | USD | 1,109 | (21,750 | ) | ||||||||||||||||
Medtronic PLC | 159 | 05/21/21 | USD | 120.00 | USD | 1,878 | (48,495 | ) | ||||||||||||||||
Merck & Co., Inc. | 132 | 05/21/21 | USD | 77.50 | USD | 1,018 | (31,350 | ) | ||||||||||||||||
Mersana Therapeutics, Inc. | 25 | 05/21/21 | USD | 20.00 | USD | 40 | (1,188 | ) | ||||||||||||||||
Mirati Therapeutics, Inc. | 55 | 05/21/21 | USD | 190.00 | USD | 942 | (33,275 | ) | ||||||||||||||||
Molecular Templates, Inc. | 39 | 05/21/21 | USD | 15.00 | USD | 49 | (3,608 | ) | ||||||||||||||||
Neurocrine Biosciences, Inc. | 27 | 05/21/21 | USD | 115.00 | USD | 263 | (7,560 | ) | ||||||||||||||||
Nevro Corp. | 28 | 05/21/21 | USD | 160.00 | USD | 391 | (9,520 | ) | ||||||||||||||||
Novocure Ltd. | 34 | 05/21/21 | USD | 165.00 | USD | 449 | (11,985 | ) | ||||||||||||||||
Oak Street Health, Inc. | 52 | 05/21/21 | USD | 65.00 | USD | 282 | (6,500 | ) | ||||||||||||||||
Pfizer, Inc. | 513 | 05/21/21 | USD | 37.00 | USD | 1,859 | (36,166 | ) | ||||||||||||||||
PPD, Inc. | 20 | 05/21/21 | USD | 40.00 | USD | 76 | (2,550 | ) | ||||||||||||||||
Prothena PLC | 21 | 05/21/21 | USD | 25.25 | USD | 53 | (7,797 | ) | ||||||||||||||||
Quest Diagnostics, Inc. | 48 | 05/21/21 | USD | 125.00 | USD | 616 | (31,680 | ) |
6 |
|
Schedule of Investments (unaudited) (continued) March 31, 2021 | BlackRock Health Sciences Trust (BME) |
Exchange-Traded Options Written (continued)
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||
Call (continued) | ||||||||||||||||||||||||
Rapt Therapeutics, Inc. | 7 | 05/21/21 | USD | 25.00 | USD | 16 | $ | (2,538 | ) | |||||||||||||||
ResMed, Inc. | 62 | 05/21/21 | USD | 195.00 | USD | 1,203 | (54,870 | ) | ||||||||||||||||
Sage Therapeutics, Inc. | 13 | 05/21/21 | USD | 100.00 | USD | 97 | (9,165 | ) | ||||||||||||||||
Silk Road Medical, Inc. | 28 | 05/21/21 | USD | 55.00 | USD | 142 | (5,600 | ) | ||||||||||||||||
Stoke Therapeutics, Inc. | 25 | 05/21/21 | USD | 70.00 | USD | 97 | (2,625 | ) | ||||||||||||||||
Stryker Corp | 110 | 05/21/21 | USD | 248.00 | USD | 2,679 | (62,623 | ) | ||||||||||||||||
TCR2 Therapeutics, Inc. | 18 | 05/21/21 | USD | 25.00 | USD | 40 | (3,420 | ) | ||||||||||||||||
Teladoc Health, Inc. | 12 | 05/21/21 | USD | 195.00 | USD | 218 | (11,940 | ) | ||||||||||||||||
Teleflex, Inc. | 34 | 05/21/21 | USD | 420.00 | USD | 1,413 | (53,550 | ) | ||||||||||||||||
UnitedHealth Group, Inc. | 51 | 05/21/21 | USD | 380.00 | USD | 1,898 | (50,872 | ) | ||||||||||||||||
Zimmer Biomet Holdings, Inc. | 156 | 05/21/21 | USD | 165.00 | USD | 2,497 | (83,460 | ) | ||||||||||||||||
Zoetis, Inc. | 126 | 05/21/21 | USD | 165.00 | USD | 1,984 | (22,050 | ) | ||||||||||||||||
Arcutis Biotherapeutics, Inc. | 43 | 06/18/21 | USD | 40.00 | USD | 124 | (10,643 | ) | ||||||||||||||||
Iovance Biotherapeutics, Inc. | 56 | 06/18/21 | USD | 40.00 | USD | 177 | (9,800 | ) | ||||||||||||||||
Prothena Corp. PLC | 38 | 06/18/21 | USD | 24.00 | USD | 95 | (18,430 | ) | ||||||||||||||||
Rapt Therapeutics, Inc. | 8 | 06/18/21 | USD | 25.00 | USD | 18 | (3,020 | ) | ||||||||||||||||
Seagen, Inc. | 120 | 06/18/21 | USD | 170.00 | USD | 1,666 | (35,400 | ) | ||||||||||||||||
Thermo Fisher Scientific, Inc. | 61 | 06/18/21 | USD | 480.00 | USD | 2,784 | (71,675 | ) | ||||||||||||||||
|
| |||||||||||||||||||||||
$ | (5,374,075 | ) | ||||||||||||||||||||||
|
|
OTC Options Written
Description | Counterparty | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | ||||||||||||||||||||
Call | ||||||||||||||||||||||||||
Forma Therapeutics Holdings, Inc. | Barclays Bank PLC | 1,200 | 04/06/21 | USD | 38.05 | USD | 34 | $ | — | |||||||||||||||||
Roche Holding AG | Goldman Sachs International | 1,100 | 04/07/21 | CHF | 304.77 | CHF | 337 | (4,560 | ) | |||||||||||||||||
Forma Therapeutics Holdings, Inc. | Barclays Bank PLC | 1,200 | 04/08/21 | USD | 38.77 | USD | 34 | (1 | ) | |||||||||||||||||
PPD, Inc. | Citibank N.A. | 6,400 | 04/08/21 | USD | 37.48 | USD | 242 | (7,113 | ) | |||||||||||||||||
Gilead Sciences, Inc. | Citibank N.A. | 42,900 | 04/09/21 | USD | 64.15 | USD | 2,773 | (48,539 | ) | |||||||||||||||||
Hansoh Pharmaceutical Group Co. Ltd. | JPMorgan Chase Bank N.A. | 80,000 | 04/13/21 | HKD | 42.90 | HKD | 2,983 | (73 | ) | |||||||||||||||||
Sanofi | Barclays Bank PLC | 11,300 | 04/13/21 | EUR | 78.85 | EUR | 953 | (73,574 | ) | |||||||||||||||||
Krystal Biotech, Inc. | Bank of America N.A. | 1,400 | 04/14/21 | USD | 81.28 | USD | 108 | (2,236 | ) | |||||||||||||||||
PPD, Inc. | Bank of America N.A. | 2,000 | 04/14/21 | USD | 37.10 | USD | 76 | (2,353 | ) | |||||||||||||||||
Genmab A/S | UBS AG | 3,200 | 04/15/21 | DKK | 2,179.08 | DKK | 6,676 | (13,683 | ) | |||||||||||||||||
Hansoh Pharmaceutical Group Co. Ltd. | JPMorgan Chase Bank N.A. | 88,000 | 04/20/21 | HKD | 35.95 | HKD | 3,282 | (20,862 | ) | |||||||||||||||||
Sanofi | Goldman Sachs International | 8,300 | 04/20/21 | EUR | 80.91 | EUR | 700 | (36,969 | ) | |||||||||||||||||
Genmab A/S | Barclays Bank PLC | 2,700 | 04/21/21 | DKK | 2,165.06 | DKK | 5,633 | (17,433 | ) | |||||||||||||||||
Merck KGaA | Barclays Bank PLC | 4,300 | 04/21/21 | EUR | 140.16 | EUR | 627 | (34,415 | ) | |||||||||||||||||
Straumann Holding AG | Barclays Bank PLC | 1,000 | 04/21/21 | CHF | 1,165.96 | CHF | 1,180 | (36,781 | ) | |||||||||||||||||
Sanofi — ADR | Barclays Bank PLC | 9,800 | 04/26/21 | USD | 49.50 | USD | 485 | (8,606 | ) | |||||||||||||||||
WuXi AppTec Co. Ltd., Class H | JPMorgan Chase Bank N.A. | 24,400 | 04/27/21 | HKD | 159.05 | HKD | 3,746 | (26,985 | ) | |||||||||||||||||
Wuxi Biologics Cayman, Inc. | JPMorgan Chase Bank N.A. | 119,000 | 04/27/21 | HKD | 94.73 | HKD | 11,666 | (90,877 | ) | |||||||||||||||||
Merck KGaA | Goldman Sachs International | 2,700 | 04/29/21 | EUR | 137.30 | EUR | 394 | (27,129 | ) | |||||||||||||||||
Hansoh Pharmaceutical Group Co. Ltd. | Goldman Sachs International | 34,000 | 05/04/21 | HKD | 36.67 | HKD | 1,268 | (7,580 | ) | |||||||||||||||||
Eisai Co. Ltd. | Morgan Stanley & Co. International PLC | 9,300 | 05/06/21 | JPY | 7,736.11 | JPY | 69,213 | (14,495 | ) | |||||||||||||||||
Hansoh Pharmaceutical Group Co. Ltd. | Citibank N.A. | 80,000 | 05/06/21 | HKD | 36.95 | HKD | 2,983 | (16,754 | ) | |||||||||||||||||
Roche Holding AG | Citibank N.A. | 2,000 | 05/06/21 | CHF | 306.91 | CHF | 612 | (13,732 | ) | |||||||||||||||||
WuXi AppTec Co. Ltd. | Morgan Stanley & Co. International PLC | 40,000 | 05/06/21 | HKD | 153.18 | HKD | 6,141 | (65,617 | ) | |||||||||||||||||
Arcutis Biotherapeutics, Inc. | Barclays Bank PLC | 3,500 | 05/11/21 | USD | 32.91 | USD | 101 | (5,440 | ) | |||||||||||||||||
Hansoh Pharmaceutical Group Co. Ltd. | Citibank N.A. | 52,000 | 05/11/21 | HKD | 37.88 | HKD | 1,939 | (8,692 | ) | |||||||||||||||||
Sanofi | UBS AG | 6,600 | 05/11/21 | EUR | 83.46 | EUR | 556 | (9,443 | ) | |||||||||||||||||
WuXi AppTec Co. Ltd. | Morgan Stanley & Co. International PLC | 15,600 | 05/14/21 | HKD | 162.41 | HKD | 2,395 | (9,839 | ) | |||||||||||||||||
PPD, Inc. | Bank of America N.A. | 2,100 | 05/26/21 | USD | 39.32 | USD | 79 | (3,427 | ) | |||||||||||||||||
|
| |||||||||||||||||||||||||
$ | (607,208 | ) | ||||||||||||||||||||||||
|
|
SCHEDULE OF INVESTMENTS | 7 |
Schedule of Investments (unaudited) (continued) March 31, 2021 | BlackRock Health Sciences Trust (BME) |
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:
• | Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access; |
• | Level 2 – Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market–corroborated inputs); and |
• | Level 3 – Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the BlackRock Global Valuation Methodologies Committee’s (the “Global Valuation Committee’s”) assumptions used in determining the fair value of financial instruments). |
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Global Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds. There may not be a secondary market, and/or there are a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust’s policy regarding valuation of financial instruments, refer to its most recent financial statements.
Certain investments of the Trust were fair valued using net asset value (“NAV”) per share as no quoted market value is available and therefore have been excluded from the fair value hierarchy.
The following table summarizes the Trust’s investments categorized in the fair value hierarchy. The breakdown of the Trust’s investments into major categories is disclosed in the Schedule of Investments above.
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Assets | ||||||||||||||||
Investments | ||||||||||||||||
Long-Term Investments | ||||||||||||||||
Common Stocks | ||||||||||||||||
Biotechnology. | $ | 95,673,617 | $ | 7,721,305 | $ | 2,375,125 | $ | 105,770,047 | ||||||||
Diversified Financial Services | 2,471,722 | — | — | 2,471,722 | ||||||||||||
Health Care Equipment & Supplies | 164,365,820 | 3,744,745 | — | 168,110,565 | ||||||||||||
Health Care Providers & Services | 114,626,696 | — | — | 114,626,696 | ||||||||||||
Health Care Technology | 3,994,865 | — | — | 3,994,865 | ||||||||||||
Insurance | 427,281 | — | — | 427,281 | ||||||||||||
Internet & Direct Marketing Retail | — | 2,296,536 | — | 2,296,536 | ||||||||||||
Life Sciences Tools & Services | 37,859,774 | 7,908,205 | — | 45,767,979 | ||||||||||||
Pharmaceuticals | 85,385,569 | 19,296,453 | — | 104,682,022 | ||||||||||||
Other Interests | — | — | 270,027 | 270,027 | ||||||||||||
Preferred Securities | ||||||||||||||||
Preferred Stocks | — | 402,275 | 3,571,516 | 3,973,791 | ||||||||||||
Warrants | 190,793 | — | — | 190,793 | ||||||||||||
Short-Term Securities | ||||||||||||||||
Money Market Funds | 11,483,604 | — | — | 11,483,604 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
$ | 516,479,741 | $ | 41,369,519 | $ | 6,216,668 | 564,065,928 | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Investments Valued at NAV(a) | 525,967 | |||||||||||||||
|
| |||||||||||||||
$ | 564,591,895 | |||||||||||||||
|
| |||||||||||||||
Derivative Financial Instruments(b) | ||||||||||||||||
Liabilities | ||||||||||||||||
Equity Contracts | $ | (5,105,625 | ) | $ | (875,658 | ) | $ | — | $ | (5,981,283 | ) | |||||
|
|
|
|
|
|
|
|
(a) | Certain investments of the Trust were fair valued using NAV per share as no quoted market value is available and therefore have been excluded from the fair value hierarchy. |
(b) | Derivative financial instruments are options written. Options written are shown at value. |
8 |
|
Schedule of Investments (unaudited) (continued) March 31, 2021 | BlackRock Health Sciences Trust (BME) |
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:
Common Stocks | Other Interests | Preferred Stocks | Total | |||||||||||||
Assets | ||||||||||||||||
Opening balance, as of December 31, 2020 | $ | 2,699,612 | $ | 254,814 | $ | 1,417,773 | $ | 4,372,199 | ||||||||
Transfers into Level 3 | — | — | — | — | ||||||||||||
Transfers out of Level 3 | (132,438 | ) | — | (250,023 | ) | (382,461 | ) | |||||||||
Other(a) | (235,430 | ) | — | 235,430 | — | |||||||||||
Accrued discounts/premiums | — | — | — | — | ||||||||||||
Net realized gain (loss) | — | — | — | — | ||||||||||||
Net change in unrealized appreciation (depreciation)(b) | 43,381 | 15,213 | 73,341 | 131,935 | ||||||||||||
Purchases | — | — | 2,094,995 | 2,094,995 | ||||||||||||
Sales | — | — | — | — | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Closing balance, as of March 31, 2021 | $ | 2,375,125 | $ | 270,027 | $ | 3,571,516 | $ | 6,216,668 | ||||||||
|
|
|
|
|
|
|
| |||||||||
Net change in unrealized appreciation (depreciation) on investments still held at March 31, 2021(b) | $ | 43,381 | $ | 15,213 | $ | 73,341 | $ | 131,935 | ||||||||
|
|
|
|
|
|
|
|
(a) | Certain Level 3 investments were re-classified between Common Stocks and Preferred Stocks. |
(b) | Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at March 31, 2021 is generally due to investments no longer held or categorized as Level 3 at period end. |
The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the “Global Valuation Committee”) to determine the value of certain of the Fund’s Level 3 investments as of period end. The table does not include Level 3 investments with values based upon unadjusted third party pricing information in the amount of $560,001. A significant change in the third party information could result in a significantly lower or higher value of such Level 3 investments.
Value | Valuation Approach | Unobservable Inputs | Range of Unobservable Inputs Utilized(a) | Weighted Average of Unobservable Inputs Based on Fair Value | ||||||||||||||||
Assets | ||||||||||||||||||||
Common Stocks | $ | 2,375,125 | Income | Discount Rate | 1% | — | ||||||||||||||
Preferred Stocks(b,c) | 3,281,542 | Market | Market Adjustment Multiple | 1.10x | — | |||||||||||||||
Volatility | 80% | — | ||||||||||||||||||
Time to Exit | 2.0 - 3.0 | 2.3 | ||||||||||||||||||
Recent Transactions | — | — | ||||||||||||||||||
Income | Discount Rate | 1% - 3% | 2% | |||||||||||||||||
|
| |||||||||||||||||||
$ | 5,656,667 | |||||||||||||||||||
|
|
(a) | A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value. |
(b) | For the period end March 31, 2021, the valuation technique for investments classified as Preferred Stocks amounting to $348,001 changed to Option Pricing Model. The investments were previously valued utilizing Transaction Price approach. The change was due to consideration of the information that was available at the time the investments were valued. |
(c) | For the period end March 31, 2021, the valuation technique for investments classified as Preferred Stocks amounting to $808,781 changed to Current Value approach. The investments were previously valued utilizing Transaction Price approach. The change was due to consideration of the information that was available at the time the investments were valued. |
Currency Abbreviation | ||
CHF | Swiss Franc | |
DKK | Danish Krone | |
EUR | Euro | |
HKD | Hong Kong Dollar | |
JPY | Japanese Yen | |
USD | United States Dollar | |
Portfolio Abbreviation | ||
ADR | American Depositary Receipt |
SCHEDULE OF INVESTMENTS | 9 |